Postoperative Pain
Conditions
Interventions
Group N50:flurbiprofen axetil 100mg and nalbuphine 50mg
Group N70:flurbiprofen axetil 100mg and nalbuphine 70mg
Group SN:flurbiprofen axetil 100mg and sufentanil 40ug, no backgroud dose
Group NN:flurbiprofen axetil 100mg and nalbuphine 40mg, no backgroud dose
Group S:flurbiprofen axetil 100mg and sufentanil 40ug
Group B:flurbiprofen axetil 100mg and butorphanol 5mg
Group N30:flurbiprofen axetil 100mg and nalbuphine 30mg
Group N40:flurbiprofen axetil 100mg and nalbuphine 40mg
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Aged 19 to 65 years; 2. ASA physical status I-II; 3. Planned to perform elective laparotomy (such as hysterectomy, hysteromyomectomy, ovarian tumor resection, etc.); 4. BMI 19-29 kg/m2; 5. Patients agree to be enrolled voluntarily in this study.
Exclusion criteria
Exclusion criteria: 1. Have a history of non-steroidal drug allergy; 2. History of neurological diseases; History of chronic pain; Drug addiction and alcohol abuse; A long history of opioid use; Opioids were administered 48 hours before surgery; 3. Coronary heart disease, bronchial asthma, severe hypertension, severe blood system dysfunction, severe liver and kidney function and electrolyte abnormalities; 4. History of gastrointestinal diseases (peptic ulcer, crohn's disease, ulcerative colitis); 5. Respiratory insufficiency and respiratory failure; 6. Patients who refused to use intravenous PCIA for analgesia; 7. Pregnant or lactating women; 8. Poor compliance, unable to complete the test according to the research plan; 9. Those who have participated in the clinical trials of other drugs in the past 4 weeks; 10. For any reason, the investigator considers that there are any circumstances that are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS; | — |
Countries
China
Contacts
Public ContactYuzhu Tao
Tianjin Medical University General Hospital
Outcome results
None listed